Last reviewed · How we verify
BPI-572270
At a glance
| Generic name | BPI-572270 |
|---|---|
| Also known as | BPI-572270 Capsule |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPI-572270 CI brief — competitive landscape report
- BPI-572270 updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI